NeoGenomics (NASDAQ:NEO) had its target price upped by SVB Leerink from $35.00 to $45.00 in a report released on Wednesday morning, The Fly reports. SVB Leerink currently has an outperform rating on the medical research company’s stock.
Other equities analysts have also issued research reports about the stock. BidaskClub raised shares of NeoGenomics from a buy rating to a strong-buy rating in a research note on Friday, July 3rd. Zacks Investment Research upgraded shares of NeoGenomics from a hold rating to a buy rating and set a $41.00 target price for the company in a research report on Wednesday. Raymond James increased their target price on shares of NeoGenomics from $32.00 to $40.00 and gave the stock an outperform rating in a research report on Wednesday. Bank of America started coverage on shares of NeoGenomics in a research report on Thursday, June 25th. They issued a buy rating and a $34.00 target price for the company. Finally, CIBC downgraded shares of NeoGenomics to a neutral rating and cut their target price for the stock from $11.00 to $9.00 in a research report on Friday, May 15th. Two equities research analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $35.80.
NeoGenomics stock opened at $38.23 on Wednesday. The company has a 50 day moving average price of $32.69 and a 200 day moving average price of $29.86. NeoGenomics has a 52 week low of $18.52 and a 52 week high of $38.74. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.88 and a current ratio of 6.79. The firm has a market capitalization of $4.03 billion, a price-to-earnings ratio of -764.60 and a beta of 0.76.
NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings data on Tuesday, July 28th. The medical research company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.06. NeoGenomics had a negative net margin of 1.33% and a positive return on equity of 0.73%. The firm had revenue of $86.90 million during the quarter, compared to analyst estimates of $86.55 million. During the same quarter last year, the business posted $0.07 EPS. The company’s revenue was down 14.6% on a year-over-year basis. Equities analysts forecast that NeoGenomics will post -0.1 earnings per share for the current fiscal year.
Institutional investors have recently added to or reduced their stakes in the company. RMB Capital Management LLC raised its holdings in NeoGenomics by 20.3% in the 1st quarter. RMB Capital Management LLC now owns 155,618 shares of the medical research company’s stock worth $4,297,000 after acquiring an additional 26,249 shares during the period. Thrivent Financial for Lutherans grew its position in NeoGenomics by 5.3% in the 1st quarter. Thrivent Financial for Lutherans now owns 87,503 shares of the medical research company’s stock worth $2,416,000 after purchasing an additional 4,368 shares during the last quarter. Exchange Traded Concepts LLC grew its position in NeoGenomics by 146.9% in the 2nd quarter. Exchange Traded Concepts LLC now owns 12,551 shares of the medical research company’s stock worth $389,000 after purchasing an additional 7,468 shares during the last quarter. State of Alaska Department of Revenue grew its position in NeoGenomics by 12.5% in the 2nd quarter. State of Alaska Department of Revenue now owns 103,575 shares of the medical research company’s stock worth $3,208,000 after purchasing an additional 11,478 shares during the last quarter. Finally, Texas Permanent School Fund grew its position in NeoGenomics by 24.5% in the 1st quarter. Texas Permanent School Fund now owns 88,912 shares of the medical research company’s stock worth $2,453,000 after purchasing an additional 17,496 shares during the last quarter. Institutional investors and hedge funds own 88.78% of the company’s stock.
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Read More: Percentage Decliners
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.